Close this search box.

We are creating some awesome events for you. Kindly bear with us.

Utilising Bio-Nanotechnology to Develop Treatment for Type 2 Diabetes

Bio Nanotechnology Treatment for Type 2 Diabetes
Photo Credit: Curtin University

Researchers from Australia’s Curtin University s have developed tiny capsules that are able to effectively target the liver and pancreas reducing the inflammatory effects of Type 2 diabetes.

About the Initiative

According to a recent press release, the research explored whether the tiny capsules could target the inflammatory effects of diabetes in mouse models over a six month period.

These were developed using bio-nanotechnologies and filled with a combination of human-based bile acids and the lipid-lowering drug Probucol.

Dr Hani Al-Salami is the lead author from the Curtin Health Innovation Research Institute (CHIRI) and the School of Pharmacy and Biomedical Sciences at Curtin University.

He explained that the tiny capsules were designed to preferentially target specific organs and enhance the delivery of the active agents, reducing potential damage to other parts of the body.

With the use of advanced and customisable bio-nanotechnologies, the team was able to generate tiny capsules that protected the active drugs during the digestive and absorptive process.

This allowed for enhanced uptake of bile acids and Probucol in the liver and pancreas, which are typically inflamed in diabetes.

They discovered that the nanoparticles containing bile acids and Probucol were effective in reducing high blood sugar levels and diabetes-associated inflammation in animal models with diabetes.

The research findings showed great promise for future diabetic treatments. However, further research was needed to test whether the treatment could also be effective in humans.

The study showed a promising link between the use of bio-nanotechnology and tissue-targeted delivery in diabetic models.

By using these advanced technologies, it may be possible to reduce the progression and severity of diabetes.

The research paper titled, ‘Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study,’ can be found online here.

It was published in the Nature journal, Scientific Reports.

Other Medical Technology Initiatives

Curtin’s innovation is just one of several medical technology initiatives around the globe. OpenGov Asia had reported on several others.

Singapore’s Agency for Science, Technology and Research (A*STAR), for instance, has been a part of two medicinal discoveries in the treatment of cancer and eye diseases.

An advanced nanocarrier for delivering anti-cancer drugs in the desired manner has been developed by researchers from A*STAR’s Institute of Bioengineering and Nanotechnology (IBN).

They created a compatible nanocarrier, which is derived from green tea catechins, for the anti-cancer drug for kidney cancer, Sunitinib (SU).

Moreover, the collaboration between researchers from the University of Florida (UF) College of Pharmacy, the Singapore Eye Research Institute (SERI) and A*STAR’s Institute of Molecular and Cell Biology (IMCB) is looking at ways of finding a drug which can treat retinal diseases.

A team of international scientists, which include a Professor from the New Zealand’s University of Auckland, had invented Artificial Neurons on Silicon Chips, which behave like the real thing.

The first-of-its-kind achievement gives enormous scope for medical devices to alleviate medical conditions such a neuronal degeneration, spinal cord injury and paralysis, and heart failure.

This opens up the possibility of curing conditions where neurons are not working properly, or have had their processes severed as in spinal cord injury, or have died.

Meanwhile, researchers from the Department of Chemistry at Hong Kong Baptist University (HKBU) have invented the world’s first multidimensional antimicrobial susceptibility testing (AST) system.

The new technology can provide information about drug-resistant pathogens present in patients, enabling doctors to accurately determine the effectiveness and appropriate dosage of antibiotics needed for effective treatment.


Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.


CTC Global Singapore, a premier end-to-end IT solutions provider, is a fully owned subsidiary of ITOCHU Techno-Solutions Corporation (CTC) and ITOCHU Corporation.

Since 1972, CTC has established itself as one of the country’s top IT solutions providers. With 50 years of experience, headed by an experienced management team and staffed by over 200 qualified IT professionals, we support organizations with integrated IT solutions expertise in Autonomous IT, Cyber Security, Digital Transformation, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Well-known for our strengths in system integration and consultation, CTC Global proves to be the preferred IT outsourcing destination for organizations all over Singapore today.


Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit


SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.


HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 


IBM is a leading global hybrid cloud and AI, and business services provider. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service.